Abbott Laboratories said patients who received its Xience drug-eluting stent had few instances of repeat procedures or major cardiac events during a one-year study on more than 2,000 patients outside the U.S. The findings are similar to results from two clinical trials that helped Abbott secure marketing approval for the device in the U.S. and Europe.

Full Story:

Related Summaries